All stock lists
Capricor Therapeutics, Inc. (NASDAQ:CAPR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
11.22+2.35 (+26.49%)
Market cap
$650M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 13, 2007
Website
Insider Score
––Not scored
CAPR Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From CAPR’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$147.5M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $92.2M
- Cash
- $44.3M
- Net debt / EBITDA
- 0.04x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $202.3M
- Current liabilities
- $29.9M
- Current ratio
- 6.77
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$104.0M
- Free cash flow
- -$129.8M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 58.1M
- Share growth (1y)
- 27.2%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CAPR Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | -100.00 % | -100.00 % | -100.00 % |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $20.36 M | $22.05 M |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$20.36 M | -$22.05 M |
| SG&A Expense | $15.12 M | $14.08 M | $9.14 M | $6.02 M | $5.92 M | $5.67 M |
| R&D Expense | $29.56 M | $28.87 M | $27.38 M | $23.13 M | $20.36 M | $22.05 M |
| Operating Expenses | $44.68 M | $42.95 M | $36.77 M | $29.16 M | $5.92 M | $5.67 M |
| Operating Income | -$44.68 M | -$42.95 M | -$36.77 M | -$29.16 M | -$26.28 M | -$27.72 M |
| Pretax Income | -$42.66 M | -$40.73 M | -$33.94 M | -$30.17 M | -$24.57 M | -$25.91 M |
| Tax Provision | $0.00 | $1.60 K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$42.66 M | -$40.73 M | -$33.94 M | -$30.17 M | -$24.57 M | -$25.91 M |
| EPS (Basic) | -$0.73 | -$0.70 | -$0.59 | -$0.62 | -$0.54 | -$0.57 |
| EPS (Diluted) | -$0.73 | -$0.70 | -$0.59 | -$0.62 | -$0.54 | -$0.57 |
| Shares Outstanding | 58.13 M | 57.93 M | 57.43 M | 48.85 M | 45.72 M | 45.71 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.